Special Issue Covering Royal Australasian
College of Surgeons 85th Annual Scientific Congress, 2–6 May 2016,
Queensland, Australia
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company ("Provectus" or “The Company”), announced
today that two abstracts related to research into IL PV-10 for
treatment for melanoma have been published in a special issue of
the ANZ Journal of Surgery detailing the Royal Australasian College
of Surgeons 85th Annual Scientific Congress, 2–6 May 2016, in
Queensland, Australia.
The first abstract, titled “Intralesional PV-10 for In-Transit
Melanoma – A Single Centre Experience,” notes that “Intralesional
PV-10 has been used at Peter MacCallum Cancer Centre since 2010,
and the current report presents a retrospective analysis of patient
outcomes, reporting the response rates, durability of responses and
observed toxicities.”
The Peter MacCallum Cancer Centre, in East Melbourne, Victoria,
Australia, is Australia’s only public hospital solely dedicated to
cancer treatment, research and education. The abstract was authored
by Jocelyn Lippey et al. and examined data from nineteen patients
receiving PV-10 at the center.
The second abstract, titled “Intralesional PV-10 Chemoablation
Therapy for the Treatment of Cutaneous Melanoma Metastases –
Results of a Prospective, Non-Randomised, Single Centre Study,”
summarizes work done at the Princess Alexandra Hospital in
Brisbane, Queensland, Australia. The authors, Tavis Read et al.,
set out “to assess the clinical efficacy and treatment outcomes of
patients receiving intralesional (IL) PV-10 chemoablation therapy
for the treatment of cutaneous melanoma metastases.” This report
examined data from forty five patients receiving PV-10 at the
hospital.
For more information about the special issue of the ANZ Journal
of Surgery where the abstracts appear, visit
http://onlinelibrary.wiley.com/doi/10.1111/ans.2016.86.issue-S1/issuetoc
(“Abstract Journal for Surgical Oncology,” pages 157-160) or
http://onlinelibrary.wiley.com/doi/10.1111/ans.13574/epdf
(abstracts SO006 and SO007).
For more information about the RACS Annual Scientific Congress,
visit: https://asc.surgeons.org.
About the Royal Australasian College of Surgeons
The Royal Australasian College of Surgeons (RACS), formed in
1927, is a non-profit organisation training surgeons and
maintaining surgical standards in Australia and New Zealand. The
College's purpose is to be the unifying force for surgery in
Australia and New Zealand, with FRACS standing for excellence in
surgical care.
About the Peter MacCallum Cancer Centre
Peter MacCallum Cancer Centre is Australia’s only public
hospital solely dedicated to cancer treatment, research and
education. The hospital treats more cancer patients each year than
any other hospital and the highly skilled medical, nursing and
allied health team is backed by the largest cancer research group
in Australia. Peter Mac has five locations across the state and
provides services to patients from across Victoria and Australia
and overseas. Multi-disciplinary teams, consisting of medical,
surgical and radiation oncologists, nurses, radiation therapists
and allied health professionals, develop comprehensive and
coordinated treatment plans, ensuring patients get treatment and a
team tailored to their individual needs. For more information,
visit http://www.petermac.org.
About Princess Alexandra Hospital
Princess Alexandra Hospital is a tertiary health care centre,
providing care in most major adult specialties. We are nationally
recognised for our expertise in trauma management and organ
transplants. We are one of Australia’s leading academic and
research health centres. For more information, visit
https://metrosouth.health.qld.gov.au/princess-alexandra-hospital.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other
clinical trials can be found at the NIH
registry, www.clinicaltrials.gov. For additional information
about Provectus, please visit the Company's website
at www.pvct.com or contact Porter, LeVay & Rose,
Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2015) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is
appropriate considering the timing and structure of such a license,
or to commercialize PV-10 on our own to treat melanoma and other
solid tumors such as cancers of the liver;
- our ability to license PH-10, our
investigational drug product for dermatology, on the basis of our
phase 2 atopic dermatitis and psoriasis results, which are in the
process of being further developed in conjunction with mechanism of
action studies; and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160428005282/en/
Porter, LeVay & Rose, Inc.Marlon Nurse, DM, 212-564-4700SVP
- Investor RelationsorAllison + PartnersTodd Aydelotte,
646-428-0644Managing Director - Media RelationsorProvectus
Biopharmaceuticals, Inc.Peter R. Culpepper, Interim CEO, COO,
866-594-5999 #30
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024